^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Koselugo (selumetinib) (MEK inhibitor) + dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors
Published date:
06/14/2010
Excerpt:
...we treated established Kras/Lkb1 lung cancers with Dasatinib alone, the combination of BEZ235 and AZD2644 (AZD/BEZ), or the combination of all three agents (Dasatinib/AZD/BEZ). Although Kras/Lkb1 lung tumors did not respond to Dasatinib or BEZ/AZD, the triple combination Dasatinib/BEZ/AZD resulted in significant tumor regression as detected by serial magnetic resonance imaging (MRI) (Figure 6A) and histology...
DOI:
10.1016/j.ccr.2010.04.026
